| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9017377 | Pulmonary Pharmacology & Therapeutics | 2005 | 7 Pages |
Abstract
Based on a retrospective analysis of 1-year, placebo-controlled clinical trials, tiotropium was associated with a reduced rate of loss of FEV1. Longer-term trials specifically designed to study this effect are required to confirm this observation.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
A. Anzueto, D. Tashkin, S. Menjoge, S. Kesten,